Pharma

The company plans to launch the injectable version of Semaglutide in a number of countries, starting with Canada in January 2026. India and Brazil will follow

Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates

Dr Reddy's Laboratories Q2 FY26 results: Dr Reddy's declares fiscal second quarter results; check net profit, revenue, margin, other details.

Laurus Labs: Is the healthy growth already priced in?

The CDMO business for small molecules grew 58 percent YoY in Q2FY26, helped by a ramp-up in sales from new manufacturing assets

Cough syrup deaths: Old regulatory failures resurface as CDSCO calls for ‘strict quality control’

The directive is similar to the one issued after India-made cough syrups were blamed for deaths of children in Gambia and Uzbekistan even as Coldrif toll climbs to 22 after two more children die

Govt invites proposals under PRIP scheme for industry, startup projects

While inviting applications, the Department of Pharmaceuticals has notified amendments to the scheme and issued revised guidelines to enhance the impact of the scheme and make it better suited to address the requirements of all stakeholders.

Select pharma shares fall between 4-7% as Trump's tariffs on branded drugs sour sentiment

At close, the Nifty Pharma index was lower by 2.14 percent and 5.2 percent for the week, with most constituents in the red.

InvAscent-backed Malladi Drugs planning Rs 1,200-crore IPO, holds talks with banks

Malladi Drugs raised Rs 250 crore from healthcare and pharma focused private equity fund InvAscent. The PE fund holds around 22-23% stake in the company

Moneycontrol Pro Panorama | A Rs 1000-crore Rx heavyweight in the making

For Moneycontrol Pro Panorama September 16 edition: Indian markets could be overestimating US Fed rate cut impact, equity tag for REITs a step towards global best practices, transformation of digital revolution and the road ahead, India’s growing influence in global diplomacy, and more

Relief for pharma sector as govt waives mandatory re-labelling of medicines after GST rate cut

NPPA directs firms to issue revised price lists instead of recalling stock; compliance to be ensured at retailer level

GST rate cuts to benefit players across the healthcare sector

Rates have been pruned for drugs used in chronic diseases as also medical devices and hospital chains

Trump doubles tariff from Aug 27: Indian labour-intensive goods face over 50%, pharma, tech remain spared

Labour-intensive exports to the US are expected to take the hardest hit as these sectors will face a rate of more than 50 percent given that Trump’s reciprocal tariffs are over and above the most favoured nation (MFN) duties in place.

India's pharma, chemical tariffs lower compared to China

India's duties on chemicals and pharmaceuticals are mostly in the range of 0-10 percent, with many pharmaceuticals at zero tariffs.

Sun Pharma: Innovative drugs are near-term growth drivers

Sun Pharma’s top line growth is steady. Innovative medicines to act as growth tonic, as the US generics business remains soft. The stock valuation is justified.

How Novo Nordisk lost its lead in the weight loss race

Drugmaker struggled to adapt to very high demand and a market where celebrities are more influential than doctors

Laurus Labs: Is it time to book profit?

The company has a CDMO pipeline of 90+ human health projects, wherein 15 products are commercialised, targeting APIs and intermediates

Cipla: Non-US markets to drive growth in the near term

Reduced contribution of Revlimid is likely to get offset by new products

Cipla Q1FY26 preview: Margin pressure likely despite double-digit India growth

Cipla is expected to post muted profit growth for Q1FY26 despite steady revenue momentum, with US sales remaining flat and margin pressure weighing on the bottom line.

Dr Reddy’s Q1FY26 preview: US headwinds may weigh on margins but revenue may see double-digit growth

Brokerages expect steady revenue growth for Dr Reddy’s in Q1FY26, but caution that US price erosion and product mix could weigh on margins and bottomline.

Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities

Net Sales are expected to increase by 5.2 percent Y-o-Y (up 7.7 percent Q-o-Q) to Rs 13,628.1 crore, according to ICICI Securities.

Cohance Lifesciences Q1 PAT may dip 64.2% YoY to Rs 51.6 cr: ICICI Securities

Net Sales are expected to decrease by 34.3 percent Y-o-Y (up 13.2 percent Q-o-Q) to Rs 552.4 crore, according to ICICI Securities.

Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities

Net Sales are expected to decrease by 9.8 percent Y-o-Y (up 16.1 percent Q-o-Q) to Rs 3,984.5 crore, according to ICICI Securities.

Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities

Net Sales are expected to increase by 1.8 percent Y-o-Y (up 2.3 percent Q-o-Q) to Rs 6,848.5 crore, according to ICICI Securities.

Pharma stocks hover near flatline even as Trump hints at new tariffs by July-end

The pharma sector will be in focus on July 16, after Donald Trump said that pharmaceuticals tariffs would be implemented soon.

A $2 billion shot in the arm: Why Glenmark’s AbbVie deal could trigger rerating

If the drug succeeds, Glenmark could be staring at a royalty stream larger than its current EBITDA.

Impending jump in patent expiries to benefit Indian pharma

Many drugs with large market potential are expected to lose exclusivity in the next couple of years